The Anixa Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
What was Anixa Biosciences’s price range in the past 12 months?
Anixa Biosciences lowest stock price was $1.70 and its highest was $8.09 in the past 12 months.
What is Anixa Biosciences’s market cap?
Anixa Biosciences’s market cap is $127.29M.
What is Anixa Biosciences’s price target?
The average price target for Anixa Biosciences is $11.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 158.82% Increase from the current price of $4.25.
What do analysts say about Anixa Biosciences?
Anixa Biosciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
When is Anixa Biosciences’s upcoming earnings report date?
Anixa Biosciences’s upcoming earnings report date is Sep 14, 2021 which is in 2 months.
How were Anixa Biosciences’s earnings last quarter?
Anixa Biosciences released its earnings results on Jun 10, 2021. The company reported -$0.084 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.021.
Is Anixa Biosciences overvalued?
According to Wall Street analysts Anixa Biosciences’s price is currently Undervalued.
Does Anixa Biosciences pay dividends?
Anixa Biosciences does not currently pay dividends.
What is Anixa Biosciences’s EPS estimate?
Anixa Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anixa Biosciences have?
Anixa Biosciences has 29,950,000 shares outstanding.
What happened to Anixa Biosciences’s price movement after its last earnings report?
Anixa Biosciences reported an EPS of -$0.084 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went up 1.667%.
Which hedge fund is a major shareholder of Anixa Biosciences?
Currently, no hedge funds are holding shares in ANIX